GO:0045786 negative regulation of cell cycle: Cell Cycle Arrest, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0045786 negative regulation of cell cycle describes any process that stops, prevents or reduces the rate or extent of progression through the cell cycle.
• It is a biological_process term that includes checkpoint-mediated arrest, downregulation of cyclin-CDK activity, and stabilization of CDK inhibitors.
• Key effectors include p53, RB1, CDKN1A (p21), CDKN2A (p16), and E2F-family transcription factors, which together link DNA damage repair to cell cycle checkpoints.
• Loss of negative cell cycle regulation is a hallmark of cancer, and restoring it is a therapeutic strategy in hepatocellular carcinoma, multiple myeloma, breast cancer, and prostate cancer.
• Beyond cancer, negative regulation of the cell cycle influences macrophage susceptibility to HIV-1 and chromatin remodeling during DNA damage responses.
• CRISPR knockout, point-mutation, knock-in, and overexpression models are used to dissect causal roles of negative cell cycle regulators in disease and development.
Description
GO:0045786 negative regulation of cell cycle is a Gene Ontology biological_process term defined as any process that stops, prevents or reduces the rate or extent of progression through the cell cycle. This term captures the molecular brakes that ensure cells divide only when appropriate, integrating signals from DNA damage checkpoints, developmental cues, and metabolic status. Because uncontrolled proliferation is a defining feature of cancer, understanding how negative regulation of the cell cycle is enforced and how it fails has direct therapeutic relevance. The term is also important in non-cancer contexts, including immune cell biology and viral infection, where cell cycle status determines susceptibility to pathogens such as HIV-1. In this article, we synthesize authoritative QuickGO annotation data with real PubMed literature to explain the mechanisms, key genes, disease links, and research methods associated with GO:0045786.
negative regulation of cell cycle At A Glance
| GO ID | GO:0045786 |
|---|---|
| GO term | negative regulation of cell cycle |
| Ontology | biological_process |
| Definition | Any process that stops, prevents or reduces the rate or extent of progression through the cell cycle. |
| Synonyms | down regulation of progression through cell cycle; down-regulation of progression through cell cycle; downregulation of progression through cell cycle; inhibition of progression through cell cycle; negative regulation of cell cycle progression; negative regulation of progression through cell cycle |
| Major function | Enforces cell cycle checkpoints and arrest in response to DNA damage, developmental signals, or metabolic stress. |
| Representative regulators | TP53, RB1, CDKN1A (p21), CDKN2A (p16), E2F transcription factors, cyclin D1. |
| Disease relevance | Cancer, viral infection susceptibility, and DNA damage repair disorders. |
| Research methods | CRISPR knockout/knock-in, RNA-seq, flow cytometry, western blot, and cell cycle reporter assays. |
What Is GO:0045786?
In our own words, GO:0045786 negative regulation of cell cycle refers to any biological process that slows, halts, or prevents the normal progression of a cell through the cell cycle. This includes checkpoint-mediated arrest at G1/S or G2/M, inhibition of cyclin-dependent kinase (CDK) activity, stabilization of CDK inhibitors, and transcriptional or post-translational suppression of factors required for S phase or mitosis. The term is a parent of more specific processes such as negative regulation of G1/S transition and negative regulation of mitotic cell cycle, and it is used to annotate gene products that actively oppose cell cycle progression.
Why Is negative regulation of cell cycle Important in Cell Biology?
Negative regulation of the cell cycle is essential for genome stability and tissue homeostasis. When these brakes fail, cells proliferate unchecked, contributing to tumorigenesis and therapy resistance. Conversely, excessive or inappropriate cell cycle arrest can impair immune responses and tissue regeneration, as seen in macrophage susceptibility to HIV-1. Understanding GO:0045786 therefore informs cancer biology, virology, and regenerative medicine, and it provides a mechanistic framework for developing targeted therapies that restore or bypass cell cycle checkpoints.
• Prevents unscheduled proliferation by enforcing G1/S and G2/M checkpoints.
• Links DNA damage repair to cell cycle arrest, preserving genomic integrity.
• Loss of negative regulation is a hallmark of many cancers, including hepatocellular carcinoma and multiple myeloma.
• Modulates susceptibility to viral infection, such as HIV-1 in macrophages.
• Influences response to anticancer drugs that target cell cycle checkpoints.
• Provides biomarkers and therapeutic targets, e.g., cyclin D1 in multiple myeloma.
• Involved in prostate cancer progression through noncoding RNA and ubiquitination pathways.
• Can be studied with CRISPR screens to identify novel negative regulators.
• Relevant to triple-negative breast cancer treatment strategies.
• Connects metabolism and cell cycle via p53-mediated pathways.
What Happens During negative regulation of cell cycle?
Checkpoint activation and DNA damage sensing
In simple terms: When DNA is damaged, cells hit the brakes on division until repairs are made.
Negative regulation of the cell cycle is initiated by checkpoint kinases that sense DNA damage and stalled replication forks. This leads to phosphorylation of downstream effectors such as p53 and RB1, which then enforce arrest. The E2F transcription factor network is a key node where negative regulators link checkpoint control to DNA damage repair. Chromatin remodelers such as Fun30 also contribute to DNA damage responses in a cell cycle-dependent manner.
CDK inhibition and cyclin downregulation
In simple terms: The molecular engines that drive cell division are switched off by inhibitor proteins.
Cell cycle progression is driven by cyclin-CDK complexes. Negative regulation involves upregulation of CDK inhibitors such as p21 (CDKN1A) and p16 (CDKN2A), which bind and inhibit CDK activity. Cyclin D1, a key regulator of G1/S transition, is also subject to negative regulation, and its dysregulation is implicated in multiple myeloma pathogenesis beyond cell cycle control. In hepatocellular carcinoma, inhibition of the PI3K/Akt pathway by Hespintor induces cell cycle arrest, demonstrating that upstream signaling can trigger negative regulation.
RB-E2F1 complex stabilization
In simple terms: A brake protein called RB holds onto E2F1, preventing it from turning on genes needed for DNA synthesis.
The RB-E2F1 complex is a central effector of negative regulation of the cell cycle. TIGAR induces p53-mediated cell cycle arrest by regulating the RB-E2F1 complex, thereby preventing E2F1-driven transcription of S-phase genes. This mechanism links metabolic stress and p53 activation to cell cycle arrest. Negative regulators of E2F transcription factors also connect checkpoint control to DNA damage repair, reinforcing the interplay between arrest and repair.
Transcriptional and post-transcriptional control
In simple terms: Cells can also stop division by shutting down the production of proteins needed for the cell cycle.
Negative regulation of the cell cycle operates at multiple levels, including transcriptional repression of cell cycle genes and post-transcriptional regulation by microRNAs and noncoding RNAs. For example, microRNA-30e negatively regulates HELLPAR, a noncoding macroRNA, and genes involved in ubiquitination and cell cycle progression in prostate cancer. This illustrates how noncoding RNAs can act as negative regulators of the cell cycle.
Integration with apoptosis and autophagy
In simple terms: When cells stop dividing, they may also activate self-destruction or recycling programs.
Negative regulation of the cell cycle is often coupled to apoptosis and autophagy. In triple-negative breast cancer cells, montelukast and zafirlukast differentially affect cell cycle regulation, apoptosis, autophagy, DNA damage, and endoplasmic reticulum stress. This crosstalk ensures that cells with irreparable damage are eliminated rather than allowed to proliferate.
Key Genes Involved in GO:0045786 negative regulation of cell cycle
The following genes and proteins are central to negative regulation of the cell cycle, based on published literature and their roles in checkpoint control, CDK inhibition, and transcriptional repression.
| Gene | Major Role | Research Relevance |
|---|---|---|
| TP53 | Induces p21 and other CDK inhibitors to enforce G1 and G2 arrest | Most frequently mutated tumor suppressor; target for cell cycle arrest studies |
| RB1 | Binds E2F1 to block S-phase gene transcription | Key effector of negative regulation; loss drives many cancers |
| CDKN1A (p21) | Inhibits CDK2 and CDK1, causing cell cycle arrest | Biomarker of p53 activity and DNA damage response |
| CDKN2A (p16) | Inhibits CDK4/6, preventing RB phosphorylation | Frequently deleted in cancers; used in senescence studies |
| E2F1 | Transcription factor for S-phase genes; negatively regulated by RB | Central node linking checkpoints and DNA repair |
| CCND1 (cyclin D1) | Regulates G1/S transition; subject to negative regulation | Therapeutic target in multiple myeloma and breast cancer |
| TIGAR | Induces p53-mediated cell cycle arrest via RB-E2F1 | Links metabolism to cell cycle control |
| Fun30 | Chromatin remodeler with cell cycle-dependent functions in DNA damage response | Model for studying chromatin and cell cycle interplay |
| HELLPAR | Noncoding macroRNA negatively regulated by miR-30e; affects cell cycle progression | Potential target in prostate cancer |
| PI3K/Akt pathway | Upstream signaling; its inhibition by Hespintor induces cell cycle arrest | Drug target in hepatocellular carcinoma |
| CDK4/6 | Kinases inhibited by p16 and p21 to enforce arrest | Targets of FDA-approved inhibitors in breast cancer |
| MDM2 | Negatively regulates p53; its inhibition stabilizes p53 and induces arrest | Target for restoring p53 function |
| ATM/ATR | DNA damage sensors that activate checkpoint kinases | Key upstream regulators of negative cell cycle control |
| CHK1/CHK2 | Effector kinases that phosphorylate p53 and CDC25 | Targets for chemosensitization |
| CDC25 | Phosphatases that activate CDKs; inhibited during arrest | Regulated by checkpoint kinases |
| WEE1 | Kinase that inhibits CDK1 to prevent mitotic entry | Target for cancer therapy |
| miR-30e | MicroRNA that negatively regulates HELLPAR and cell cycle genes | Therapeutic candidate in prostate cancer |
How Is negative regulation of cell cycle Regulated?
Negative regulation of the cell cycle is itself tightly regulated by upstream signaling pathways. The PI3K/Akt pathway promotes proliferation, and its inhibition by agents such as Hespintor induces cell cycle arrest in hepatocellular carcinoma. The p53-MDM2 axis controls the stability of p53, which in turn activates p21 and other negative regulators. Metabolic stress can also feed into this network via TIGAR, which modulates the RB-E2F1 complex to induce arrest. In addition, noncoding RNAs such as miR-30e can post-transcriptionally regulate genes involved in cell cycle progression. These layers of regulation ensure that cell cycle arrest is reversible and context-dependent.
negative regulation of cell cycle and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TP53 | Li-Fraumeni syndrome, many cancers | TP53 knockout and point-mutation cell lines |
| CCND1 | Multiple myeloma, breast cancer | Cyclin D1 overexpression and knockout models |
| HELLPAR | Prostate cancer | CRISPR knockout of HELLPAR in prostate cancer cells |
| PI3K/Akt | Hepatocellular carcinoma | Hespintor treatment and pathway inhibition |
| E2F1 | DNA damage repair disorders | E2F1 knockout and reporter assays |
Cancer: loss of negative regulation drives proliferation
In many cancers, negative regulators of the cell cycle are mutated or silenced, leading to unchecked proliferation. In hepatocellular carcinoma, inhibition of the PI3K/Akt pathway by Hespintor induces cell cycle arrest, suggesting that restoring negative regulation is therapeutic. In multiple myeloma, cyclin D1 dysregulation contributes to pathogenesis beyond cell cycle control, highlighting the complexity of targeting this pathway. In prostate cancer, microRNA-30e negatively regulates HELLPAR and cell cycle genes, and its anticancer function is mediated by this negative regulation. Triple-negative breast cancer cells respond to montelukast and zafirlukast with altered cell cycle regulation, apoptosis, and autophagy, indicating that negative regulation can be pharmacologically modulated.
Viral infection: cell cycle status affects susceptibility
Cell cycle regulation in macrophages influences susceptibility to HIV-1. Negative regulation of the cell cycle may create a cellular state that is more or less permissive to viral replication. This link between cell cycle control and viral infection suggests that modulating negative regulators could affect host-pathogen interactions.
DNA damage repair disorders
Negative regulation of the cell cycle is intimately linked to DNA damage repair. Defects in this coordination can lead to genomic instability. For example, the E2F negative regulator links cell cycle checkpoints to DNA damage repair, and the Fun30 chromatin remodeler has cell cycle-dependent functions in the DNA damage response. Disruption of these processes may contribute to diseases characterized by DNA repair defects.
From negative regulation of cell cycle-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a candidate gene abolish cell cycle arrest? | CRISPR knockout in cancer cell lines |
| Does a specific point mutation in TP53 impair arrest? | Point-mutation knock-in via CRISPR |
| Does overexpression of a negative regulator induce arrest? | Doxycycline-inducible overexpression |
| Where does a negative regulator localize during arrest? | Tagged knock-in with fluorescent protein |
| Which genes are essential for checkpoint recovery? | Genome-wide CRISPR library screening |
| Does a noncoding RNA regulate cell cycle genes? | CRISPR interference or knockout of lncRNA |
How to Study the negative regulation of cell cycle Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Flow cytometry | Cell cycle phase distribution | Confirming G1 or G2 arrest |
| Western blot | Protein expression and phosphorylation | Detecting p53, p21, RB changes |
| Immunoprecipitation | Protein-protein interactions | Assessing RB-E2F1 complex |
| RNA-seq | Global transcriptome changes | Identifying E2F targets and lncRNAs |
| CRISPR knockout screen | Gene essentiality for arrest | Discovering novel negative regulators |
| Reporter assays | Transcriptional activity of E2F | Measuring negative regulation of E2F |
| Cell viability assay | Proliferation and survival | Linking arrest to growth inhibition |
| qPCR | mRNA levels of cell cycle genes | Validating RNA-seq findings |
Flow cytometry and cell cycle analysis
Flow cytometry with DNA dyes such as propidium iodide is the standard method to measure cell cycle distribution and arrest. It can quantify the percentage of cells in G1, S, and G2/M phases after genetic or pharmacological perturbation. This method is often used to confirm that a candidate negative regulator induces arrest.
Western blot and immunoprecipitation
Western blotting detects changes in key cell cycle regulators such as p53, p21, RB, and cyclin D1. Immunoprecipitation can assess complex formation, such as the RB-E2F1 interaction. These methods are essential for validating mechanisms of negative regulation.
RNA-seq and transcriptomics
RNA sequencing reveals global transcriptional changes upon induction of negative regulation. It can identify E2F target genes and noncoding RNAs such as HELLPAR that are repressed during arrest. This approach is powerful for discovering novel regulators and biomarkers.
CRISPR screens and functional genomics
Genome-wide CRISPR knockout or activation screens can identify genes whose loss or gain affects cell cycle arrest. Such screens have been used to link E2F regulators to DNA damage repair and to find noncoding RNA modulators of cell cycle progression. These methods are high-throughput and unbiased.
How CRISPR Can Be Used to Study GO:0045786 negative regulation of cell cycle
Knockout
CRISPR knockout is used to delete negative regulators such as TP53, CDKN1A, or RB1 to test whether cells lose the ability to arrest. For example, knocking out E2F negative regulators can reveal their role in DNA damage repair. Knockout of noncoding RNAs like HELLPAR can show their impact on cell cycle progression.
Point Mutation
Point mutations in genes like TP53 can be introduced to model cancer-associated missense mutations that impair cell cycle arrest. This allows researchers to distinguish loss-of-function from dominant-negative effects. Such models are valuable for drug sensitivity testing.
Knock-in
Knock-in of tagged versions of proteins such as RB1 or E2F1 enables live-cell imaging and interaction studies. This can reveal dynamic changes in complex formation during cell cycle arrest. Knock-in of reporter genes under cell cycle promoters can also monitor arrest in real time.
Overexpression
Overexpression of negative regulators like p21, TIGAR, or Hespintor can induce cell cycle arrest in cancer cells. This approach is used to test therapeutic potential and to study downstream mechanisms. Inducible overexpression systems allow precise temporal control.
How EDITGENE Supports negative regulation of cell cycle Research
Researchers studying negative regulation of cell cycle-related genes often need to determine whether a candidate gene is causally involved in arrest, proliferation, or disease progression. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models for such studies.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of cell cycle research.
Frequently Asked Questions About negative regulation of cell cycle
What is GO:0045786 negative regulation of cell cycle?
GO:0045786 is a Gene Ontology biological_process term defined as any process that stops, prevents or reduces the rate or extent of progression through the cell cycle.
What genes are involved in negative regulation of the cell cycle?
Key genes include TP53, RB1, CDKN1A (p21), CDKN2A (p16), E2F1, and CCND1, among others.
How does p53 negatively regulate the cell cycle?
p53 induces CDK inhibitors such as p21 and can regulate the RB-E2F1 complex, leading to cell cycle arrest.
What is the role of RB-E2F1 in cell cycle arrest?
RB binds E2F1 to prevent transcription of S-phase genes, and this complex is stabilized during p53-mediated arrest.
How is negative regulation of the cell cycle studied?
Common methods include flow cytometry, western blot, RNA-seq, and CRISPR screens.
What diseases are linked to defective negative regulation of the cell cycle?
Cancer, including hepatocellular carcinoma, multiple myeloma, prostate cancer, and breast cancer, as well as viral infection susceptibility.
Can CRISPR be used to study negative regulation of the cell cycle?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are widely used to dissect gene function in this process.
What is the difference between negative regulation of cell cycle and cell cycle arrest?
Cell cycle arrest is a specific outcome, while negative regulation of the cell cycle encompasses any process that reduces progression, including arrest, slowed progression, or prevention of entry into the cycle.
Which noncoding RNAs regulate the cell cycle negatively?
MicroRNA-30e negatively regulates HELLPAR and genes involved in cell cycle progression in prostate cancer.
How does the PI3K/Akt pathway affect negative regulation of the cell cycle?
Inhibition of PI3K/Akt by Hespintor induces cell cycle arrest in hepatocellular carcinoma, showing that this pathway opposes negative regulation.
Conclusion
GO:0045786 negative regulation of cell cycle is a fundamental biological process that safeguards genome integrity and tissue homeostasis. Its dysregulation contributes to cancer and influences viral infection susceptibility. By integrating QuickGO definitions with real PubMed evidence, this article highlights the key genes, mechanisms, and research methods for studying this process. CRISPR-based models from EDITGENE can accelerate discoveries in this field, from knockout screens to precise point mutations.
References
- 1. Sun J et al.. 2024. Hespintor Negative Regulation of PI3K/Akt Pathway Induces Cell Cycle Arrest of Hepatocellular Carcinoma.. Bull Exp Biol Med 178(2):237-243 PMID: 39762705
- 2. Wang L et al.. 2018. Negative regulator of E2F transcription factors links cell cycle checkpoint and DNA damage repair.. Proc Natl Acad Sci U S A 115(16):E3837-E3845 PMID: 29610335
- 3. Cardona-Benavides IJ et al.. 2025. Exploring the role of cyclin D1 in the pathogenesis of multiple myeloma beyond cell cycle regulation.. Mol Oncol 19(11):3175-3192 PMID: 40674249
- 4. Siler J et al.. 2017. Cell cycle-dependent positive and negative functions of Fun30 chromatin remodeler in DNA damage response.. DNA Repair (Amst) 50:61-70 PMID: 28089177
- 5. Ferreira IATM et al.. 2020. Cell Cycle Regulation in Macrophages and Susceptibility to HIV-1.. Viruses 12(8) PMID: 32751972
- 6. Vivithanaporn P et al.. 2024. Differential effects of montelukast and zafirlukast on MDA‑MB‑231 triple‑negative breast cancer cells: Cell cycle regulation, apoptosis, autophagy, DNA damage and endoplasmic reticulum stress.. Mol Med Rep 30(2) PMID: 38904207
- 7. Ganapathy K et al.. 2022. Anticancer function of microRNA-30e is mediated by negative regulation of HELLPAR, a noncoding macroRNA, and genes involved in ubiquitination and cell cycle progression in prostate cancer.. Mol Oncol 16(16):2936-2958 PMID: 35612714
- 8. Madan E et al.. 2012. TIGAR induces p53-mediated cell-cycle arrest by regulation of RB-E2F1 complex.. Br J Cancer 107(3):516-26 PMID: 22782351
